Summary
AI-generated response text is not provided; only a list of claims is available. Therefore, the response cannot be fully verified against the supplied FDA label excerpts beyond general, non-unique thematic alignment.
Category Scores
Accurate Statements
Unsupported Statements
Venlafaxine hydrochloride is used to treat major depressive disorder (depression).
No supported label excerpt for indications was provided in the prompt.
Venlafaxine hydrochloride is used to treat generalized anxiety disorder.
No supported label excerpt for indications was provided in the prompt.
Venlafaxine hydrochloride is used to treat panic disorder.
No supported label excerpt for indications was provided in the prompt.
Venlafaxine is an antidepressant.
Label excerpts provided focus on suicidality/MAOI/pediatric; no explicit statement in the excerpts that venlafaxine is an antidepressant.
Venlafaxine affects brain chemicals involved in mood and anxiety.
No mechanistic/brain-chemicals statement is included in the provided label excerpts.
By changing the balance of neurotransmitters, venlafaxine can reduce depressive symptoms.
No neurotransmitter-mechanism or efficacy statement is included in the provided label excerpts.
By changing the balance of neurotransmitters, venlafaxine can reduce anxiety symptoms such as persistent worry.
No neurotransmitter-mechanism or anxiety-efficacy timing statement is included in the provided label excerpts.
By changing the balance of neurotransmitters, venlafaxine can reduce anxiety symptoms such as panic attacks.
No neurotransmitter-mechanism or panic disorder efficacy statement is included in the provided label excerpts.
Symptoms often improve gradually rather than immediately after starting venlafaxine.
No onset-of-improvement information is included in the provided label excerpts.
Many people notice some change within the first couple of weeks after starting venlafaxine.
No timeframe for improvement is included in the provided label excerpts.
Fuller benefit from venlafaxine may take longer depending on the condition being treated.
No label excerpt in the prompt discusses comparative time to full benefit by condition.
Venlafaxine may be prescribed for other off-label uses depending on clinician judgment and local prescribing practices.
No label excerpt provided addresses off-label prescribing.
Common early concerns with venlafaxine can include increased anxiety or restlessness soon after starting.
No adverse reaction or early-worsening description for these specific symptoms is included in the provided label excerpts.
Common early concerns with venlafaxine can include sleep changes.
No adverse reaction/sleep-related information is included in the provided label excerpts.
Common early concerns with venlafaxine can include nausea.
No adverse reaction information is included in the provided label excerpts.
Common early concerns with venlafaxine can include headache.
No adverse reaction information is included in the provided label excerpts.
Withdrawal or missed doses of venlafaxine can cause unpleasant symptoms.
No discontinuation/withdrawal or missed-dose counseling is included in the provided label excerpts.
Contradictions
Important Omissions
Suicidality monitoring language (e.g., monitor closely, emergence of suicidal thoughts/behavior, especially during initial months/dose changes) corresponding to the provided boxed warning/Section 5.1/Section 17 excerpts.
Importance:
Moderate
Pediatric restriction/approval status (venlafaxine hydrochloride extended-release capsules are not approved for pediatric patients) as referenced in the boxed warning and Section 8.4.
Importance:
Moderate
Contraindication related to concomitant use with MAOIs and related serotonin syndrome risk (Sections 4.2, plus cross-references to 5.2/7.* per provided excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The provided label excerpts emphasize boxed warning and close monitoring for suicidality plus pediatric non-approval and MAOI contraindication. The listed claims do not include these required safety elements, and several claims (indications, adverse effects, withdrawal) are unsupported by the provided excerpts, which could lead to incomplete risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most claims (indications, mechanism, onset/timing, common early adverse effects, withdrawal, and off-label prescribing) are not supported by the supplied FDA label excerpts; key boxed-warning/pediatric and MAOI contraindication safety content is not reflected.
Suggested Improvement
Limit claims to information directly supported by the provided label excerpts; explicitly include boxed warning/Section 5.1/Section 17 monitoring and pediatric non-approval, and include the MAOI contraindication excerpt when discussing contraindications.